Dapsone-induced Hemolytic Anemia in Lung Allograft Recipients
Authors:
- G. Marshall LyonGLG. Marshall Lyon
- Allan RamirezARAllan Ramirez
- E. Clinton LawrenceELE. Clinton Lawrence
- David C. NeujahrDNDavid C. Neujahr
- Seth ForceSFSeth Force
- Andres PelaezAPAndres Pelaez
- 1 November 2008
- journal article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (11) , 1198-1202
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Complications Related to Dapsone Use for Pneumocystis Jirovecii Pneumonia Prophylaxis in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2005
- Prevention of Infection Due toPneumocystisspp. in Human Immunodeficiency Virus-Negative Immunocompromised PatientsClinical Microbiology Reviews, 2004
- Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons—2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America*Annals of Internal Medicine, 2002
- Dapsone and sulfones in dermatology: Overview and updateJournal of the American Academy of Dermatology, 2001
- Development of dapsone toxicity in patients with inflammatory dermatoses: Activity of acetylation and hydroxylation of dapsone as risk factorsClinical Pharmacology & Therapeutics, 1999
- Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Recipients Ever Be Discontinued?Clinical Infectious Diseases, 1999
- Use of Dapsone in the Prevention and Treatment ofPneumocystis cariniiPneumonia: A ReviewClinical Infectious Diseases, 1998
- Prevention and Treatment of Pneumocystis PneumoniaNew England Journal of Medicine, 1992
- Unexpectedly High Incidence of Pneumocystis carinii Infection after Lung-Heart Transplantation: Implications for Lung Defense and Allograft SurvivalAmerican Review of Respiratory Disease, 1988
- INFECTIONS IN HEART-LUNG TRANSPLANT RECIPIENTSTransplantation, 1986